BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29127861)

  • 1. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of EZH2 expression in myelodysplastic syndromes.
    Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
    Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
    Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Expression of
    de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
    Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
    Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
    Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
    Xu F; Li X
    Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
    Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
    Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
    Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ineffective erythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
    Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
    Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dyserythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.
    Kawabata KC; Hayashi Y; Inoue D; Meguro H; Sakurai H; Fukuyama T; Tanaka Y; Asada S; Fukushima T; Nagase R; Takeda R; Harada Y; Kitaura J; Goyama S; Harada H; Aburatani H; Kitamura T
    Leukemia; 2018 Feb; 32(2):419-428. PubMed ID: 28720764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
    Sakhdari A; Class C; Montalban-Bravo G; Sasaki K; Bueso-Ramos CE; Patel KP; Routbort MJ; Loghavi S; Ok CY; Quesada A; Khoury JD; Konoplev SN; Kantarjian HP; Garcia-Manero G; Medeiros LJ; Kanagal-Shamanna R
    Mod Pathol; 2022 Sep; 35(9):1212-1219. PubMed ID: 35504958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
    Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
    Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.